Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and ...

Azacitidine and decitabine belong to a class of antineoplastic agents known as DNA methyltransferase inhibitors (DMTIs). Each is paired with cedazuridine, a cytidine deaminase inhibitor, to help the ...

Solu Therapeutics Announces Presentation of Trial in Progress on STX-0712 for Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that it will present ...
Healio

VIDEO: Timdarpacept ‘might have legs’ in chronic myelomonocytic leukemia treatment

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Merin, director of the leukemia program at Cedars-Sinai ...
Business Wire

Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...
Morningstar

Solu Therapeutics Presents Positive Preclinical Data on STX-0712 for Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting

BOSTON, Dec. 9, 2024 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...
Healio

VIDEO: Timdarpacept examined in dedicated chronic myelomonocytic leukemia trial

Please provide your email address to receive an email when new articles are posted on . In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic ...

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

The abstract can be found on the ASH Annual Meeting website, https://submit.hematology.org/program/presentation/674309 ...
MedPage Today

Chronic Myelomonocytic Leukemia Survival: The Care Center Matters

"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...
Targeted Oncology

Oral Decitabine/Cedazuridine Plus Venetoclax Shows High Response Rate in MDS/CMML

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...
WLNS.com

Solu Therapeutics to Present First Preclinical Data of STX-0712 for the Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting

BOSTON, Dec. 2, 2024 /PRNewswire/ -- Solu Therapeutics ("Solu Therapeutics" or "Solu"), a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and ...